Long‐Term Outcomes in Children With Congenital Cytomegalovirus Infection
Laryngoscope Investigative Otolaryngology · 2026-04 · 11 (2)
DOI: 10.1002/lio2.70386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laryngoscope Investigative Otolaryngology, online erschienen am 30.03.2026. Verfasst von Noriko Morimoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology National Center for Child Health and Development Tokyo Japan. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
We aimed to evaluate the long‐term auditory outcomes of early antiviral therapy with valganciclovir (VGCV) in children with congenital cytomegalovirus (cCMV) infection, regardless of initial symptomatology.
Methods
This retrospective cohort study included 56 pediatric patients (112 ears) diagnosed with cCMV infection between 2004 and 2022 at our institution. The participants were divided into those who received (treated group, n = 19) and did not receive (untreated group, n = 37) VGCV or ganciclovir therapy. Audiological assessments were conducted over a minimum 2‐year follow‐up period (range, 2–15 years). Furthermore, hearing thresholds were evaluated longitudinally, with a decline of ≥ 10 dB being defined as significant. The primary outcomes were hearing loss progression and age at onset.
Results
At the final follow‐up, there were no significant between‐group differences in the prevalence or severity of hearing loss. However, fewer ears showed significant hearing deterioration in the treated group (26%) than in the untreated group (41%, p < 0.01). Furthermore, the magnitude of hearing decline was smaller in the treated group (35.0 ± 13.8 dB) than in the untreated group (67.4 ± 19.2 dB) ( p < 0.002). Hearing loss in treated patients stabilized by the age of 3 years; in contrast, untreated patients experienced multiple deterioration episodes even after this age.
Conclusions
Early VGCV treatment may help stabilize hearing and reduce long‐term hearing deterioration in children with cCMV infections. This highlights the importance of early intervention and hearing surveillance, especially in untreated individuals. Level of Evidence 4
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology National Center for Child Health and Development Tokyo Japan.
ORCID-Profile: Noriko Morimoto
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Morimoto, N., Suzuki, N., Imamura, K., Saikawa, T., & Miyoshi, N. (2026). Long‐Term Outcomes in Children With Congenital Cytomegalovirus Infection. Laryngoscope Investigative Otolaryngology, 11(2). https://doi.org/10.1002/lio2.70386
Vancouver
Morimoto N, Suzuki N, Imamura K, Saikawa T, Miyoshi N. Long‐Term Outcomes in Children With Congenital Cytomegalovirus Infection. Laryngoscope Investigative Otolaryngology. 2026;11(2). doi:10.1002/lio2.70386
BibTeX
@article{Morimoto2026,
author = {Morimoto, Noriko and Suzuki, Noriomi and Imamura, Kanako and Saikawa, Tomohiro and Miyoshi, Naoto},
title = {Long‐Term Outcomes in Children With Congenital Cytomegalovirus Infection},
journal = {Laryngoscope Investigative Otolaryngology},
year = {2026},
volume = {11},
number = {2},
doi = {10.1002/lio2.70386}
}
EUVIMED